In colon cancer cells, activation of AKT1 and AKT3 results in the abnormal suppression of miR-125b-5p, which subsequently leads to the upregulation of GLUT5 expression, causing metastasis and drug resistance in colon cancer cells 18. Here, SLC2A5 is linked to malignant colon neoplasm.